Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-10-15

Clinical Trial Update: Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ALXN1840 versus standard of care in pediatric Wilson disease participants was terminated, and trial results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALXN1840 (ALXN1840)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Wilson Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-10-15